ClinicalTrials.gg
RecruitingNCT07716488FAMELIPIDCHILDUpdated Jul 21, 2026

Screening for Disorders of Lipid Metabolism and Familial Hyperlipidemia in Children and Adolescents With Increased Cardiovascular Risk Due to Chronic Diseases Such as Congenital Heart Disease, Chronic Inflammatory Bowel Disease, Celiac Disease and Rheumatic Disorders

An interventional study of blood test, questionaire in Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors and Congenital Heart Disease, sponsored by Alexandra Miriam Kiess. Recruiting at 1 site in Germany. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-07-21.

Primary conditionLipid Metabolism, Inborn ErrorsRegistry: Lipid Metabolism DisordersReclassifiedWhy we changed it
Registry
Lipid Metabolism Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lipid Metabolism, Inborn Errors
Why
  1. The study's listed conditions name Lipid Metabolism, Inborn Errors, a narrower term within Lipid Metabolism Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Alexandra Miriam Kiess · Not applicable, Interventional, and Screening

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Not applicable
Ages
6 Years to 18 Years
Sex
All
01

Study summary

Preventive measures are increasingly coming to the forefront of medicine. Many of these measures can be implemented as early as childhood and adolescence. For instance, the early detection and treatment of cardiovascular risk factors can significantly reduce long-term morbidity and mortality associated with cardiovascular diseases such as heart attack and stroke. For years, there has been discussion in Germany about assessing lipid profiles during childhood and adolescence to enable early intervention in cases of conditions like familial hypercholesterolemia. However, comprehensive screening has not yet been established in either clinical guidelines or routine practice. In other countries, such as Norway, universal screening has been conducted for many years and has already demonstrated both its benefits and cost-effectiveness. In Germany, screening, and subsequent early treatment if needed, is currently limited to a small number of children and adolescents-such as patients with type 1 diabetes mellitus (T1DM)-as part of their routine preventive check-ups. The prevalence of dyslipidemia in T1DM is approximately 15%. Reliable prevalence data are lacking for almost all other chronic conditions affecting children and adolescents (e.g., inflammatory bowel disease, celiac disease, rheumatic diseases, congenital heart defects). Through a pilot project at Jena University Hospital, we aim to screen children and adolescents with chronic conditions who are already at increased cardiovascular risk due to their underlying diseases. The project will record lipid levels, clinical data, family history, and lifestyle factors. The results of this study enable us, on the one hand, to help the individual through early diagnosis and consequent treatment recommendations; on the other hand, the data provide important information regarding the prevalence of hyperlipidemia and other risk factors-such as physical inactivity-within this high-risk cohort.

02

Conditions studied

  • Lipid Metabolism Disorders
  • Lipid Metabolism, Inborn Errors
  • Congenital Heart Disease
  • Inflammatory Bowel Disease (IBD)
  • Rheumatic Diseases
  • Celiac Disease in Children
  • Celiac Disease in Adolescents

Keywords

  • lipid metabolism disorders
  • chronic disease
  • children
  • adolescents
03

In context

Lipid Metabolism, Inborn Errors Reclassified

24 studies on the registry are indexed under Lipid Metabolism, Inborn Errors; 3 are open to participants now.

This study's planned enrollment of 600 is above the median of 38 across 18 interventional studies indexed under Lipid Metabolism, Inborn Errors.

Browse Lipid Metabolism, Inborn Errors studies →

Lead sponsor

This is the only study on the registry with Alexandra Miriam Kiess as lead sponsor.

Compared within Lipid Metabolism, Inborn Errors, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lipid Metabolism Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Patients aged 5 to 18 years who are being treated at the UKJ in one of our specialized pediatric clinics for a chronic condition-such as a congenital heart defect, chronic inflammatory bowel disease, celiac disease, or a rheumatic disease.

Exclusion Criteria: Lack of consent from the patient or legal guardian(s)

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Other
    screening

    blood test, questionaire, clinical data

    Other: blood test, questionaire

Interventions

  • Otherblood test, questionaire

    blood test + questionaire

06

What researchers measure

Primary outcomes

  1. Prevalence of elevated lipid levels and familial hyperlipidemias in our sample of chronically ill children and adolescents

    Time frame: 6-12 months

Secondary outcomes

  1. Determination of the magnitude of elevations (mean and standard deviation [SD], and-where comparative data exist-age-appropriate percentiles) of: LDL cholesterol and lipoprotein(a), as well as total and HDL cholesterol, triglycerides, and homocysteine

    Time frame: 6-12 months

  2. Correlation of the measured laboratory parameters with height, weight, BMI, comorbidities, medication, age, and sex, as well as lifestyle factors and family history.

    Time frame: 6-12 months

  3. Investigation of whether the prevalence differs from that of the general population and from a further comparison group-patients treated at our center for type 1 diabetes mellitus, for whom this screening has been established for years.

    Time frame: 6-12 months

  4. Prevalence of unhealthy lifestyle (lack of physical activity, high media consumption, unhealthy eating habits) and familial predisposition regarding cardiovascular risk factors, and their correlation with the measured lipid levels, in our cohort

    Time frame: 6-12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Jan 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2026
First posted
Jul 21, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Jan 31, 2027
CompletionEst.
Apr 30, 2027
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07716488
Lead sponsor
Alexandra Miriam Kiess
Responsible party
Alexandra Miriam Kiess (Principal investigator, Jena University Hospital) — Sponsor-investigator
First posted
Jul 21, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Jan 31, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Jul 21, 2026

Study contacts

Alexandra M Kiess, MD
Contact
AlexandraMiriam.Kiess@med.uni-jena.de
0049-3641-9329578
Alexandra M Kiess, MD
principal investigator · University Hospital Jena

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion